Drug Profile
Research programme: Macrocyclic compounds - Cyclenium Pharma/University of Sherbrooke
Latest Information Update: 13 Jun 2023
Price :
$50
*
At a glance
- Originator Cyclenium Pharma; University of Sherbrooke
- Class Macrocyclic compounds; Opioid analgesics
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 06 Jun 2023 Cyclenium Pharma has been acquired by SpiroChem
- 28 Aug 2021 No recent reports of development identified for research development in Pain in Canada
- 25 Jul 2017 Early research in Pain in Canada before July 2017 (Cyclenium Pharma pipeline, July 2017)